Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting

Results of two pilot trials

Jacob Bleicher, Achala Bhaskara, Tim Huyck, Susan Constantino, Aditya Bardia, Charles L. Loprinzi, Peter T. Silberstein

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Despite their use of prophylactic antiemetic therapies, cancer patients continue to consider chemotherapy-induced nausea and vomiting (CINV) to be a significant problem. Patients frequently use various "breakthrough" medications for these symptoms. Unfortunately, there is a paucity of trials regarding treatment of breakthrough CINV. This study investigated the efficacy of "ABH," a topical gel containing lorazepam (Ativan), diphenhydramine (Benadryl), and haloperidol (Haldol), in reducing breakthrough CINV. Adults receiving standard recommended prophylactic antiemetics as outpatients were instructed to use 0.5 mL of the gel topically when they experienced significant CINV. Patients then were contacted retrospectively to respond to a questionnaire rating their nausea and/or vomiting and their response to ABH-gel treatment. The results were collected during two trials: Trial I began in April 2003, and Trial II began in March 2006. During Trial I, 23 patients were evaluated; 17 patients (74%) reported that use of the gel decreased their CINV, with 15 (70%) reporting relief within 30 minutes of its application.Three patients believed that the gel caused sedation; no troubles with skin irritation or muscle spasms were reported. In Trial II, all 10 patients believed that the treatment was effective. When the severity of CINV was quantified on a scale of 0-10, the mean CINV score decreased significantly from a 6.1 before gel application to a 1.7 as evaluated 30 minutes following gel application (P<0.005).Topical use of ABH gel appears to be a promising and safe rescue therapy for breakthrough CINV that occurs despite prophylactic antiemetic therapy. These results warrant further confirmation in a large, randomized, placebo-controlled trial.

Original languageEnglish
Pages (from-to)27-32
Number of pages6
JournalJournal of Supportive Oncology
Volume6
Issue number1
StatePublished - Jan 2008

Fingerprint

Lorazepam
Diphenhydramine
Haloperidol
Nausea
Vomiting
Gels
Drug Therapy
Antiemetics
Therapeutics
Spasm
Outpatients
Randomized Controlled Trials
Placebos
Skin

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting : Results of two pilot trials. / Bleicher, Jacob; Bhaskara, Achala; Huyck, Tim; Constantino, Susan; Bardia, Aditya; Loprinzi, Charles L.; Silberstein, Peter T.

In: Journal of Supportive Oncology, Vol. 6, No. 1, 01.2008, p. 27-32.

Research output: Contribution to journalArticle

Bleicher, Jacob ; Bhaskara, Achala ; Huyck, Tim ; Constantino, Susan ; Bardia, Aditya ; Loprinzi, Charles L. ; Silberstein, Peter T. / Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting : Results of two pilot trials. In: Journal of Supportive Oncology. 2008 ; Vol. 6, No. 1. pp. 27-32.
@article{84f9074e72c847549d55f4de20951446,
title = "Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: Results of two pilot trials",
abstract = "Despite their use of prophylactic antiemetic therapies, cancer patients continue to consider chemotherapy-induced nausea and vomiting (CINV) to be a significant problem. Patients frequently use various {"}breakthrough{"} medications for these symptoms. Unfortunately, there is a paucity of trials regarding treatment of breakthrough CINV. This study investigated the efficacy of {"}ABH,{"} a topical gel containing lorazepam (Ativan), diphenhydramine (Benadryl), and haloperidol (Haldol), in reducing breakthrough CINV. Adults receiving standard recommended prophylactic antiemetics as outpatients were instructed to use 0.5 mL of the gel topically when they experienced significant CINV. Patients then were contacted retrospectively to respond to a questionnaire rating their nausea and/or vomiting and their response to ABH-gel treatment. The results were collected during two trials: Trial I began in April 2003, and Trial II began in March 2006. During Trial I, 23 patients were evaluated; 17 patients (74{\%}) reported that use of the gel decreased their CINV, with 15 (70{\%}) reporting relief within 30 minutes of its application.Three patients believed that the gel caused sedation; no troubles with skin irritation or muscle spasms were reported. In Trial II, all 10 patients believed that the treatment was effective. When the severity of CINV was quantified on a scale of 0-10, the mean CINV score decreased significantly from a 6.1 before gel application to a 1.7 as evaluated 30 minutes following gel application (P<0.005).Topical use of ABH gel appears to be a promising and safe rescue therapy for breakthrough CINV that occurs despite prophylactic antiemetic therapy. These results warrant further confirmation in a large, randomized, placebo-controlled trial.",
author = "Jacob Bleicher and Achala Bhaskara and Tim Huyck and Susan Constantino and Aditya Bardia and Loprinzi, {Charles L.} and Silberstein, {Peter T.}",
year = "2008",
month = "1",
language = "English",
volume = "6",
pages = "27--32",
journal = "Journal of Supportive Oncology",
issn = "1544-6794",
publisher = "Biolink Communications, Inc.",
number = "1",

}

TY - JOUR

T1 - Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting

T2 - Results of two pilot trials

AU - Bleicher, Jacob

AU - Bhaskara, Achala

AU - Huyck, Tim

AU - Constantino, Susan

AU - Bardia, Aditya

AU - Loprinzi, Charles L.

AU - Silberstein, Peter T.

PY - 2008/1

Y1 - 2008/1

N2 - Despite their use of prophylactic antiemetic therapies, cancer patients continue to consider chemotherapy-induced nausea and vomiting (CINV) to be a significant problem. Patients frequently use various "breakthrough" medications for these symptoms. Unfortunately, there is a paucity of trials regarding treatment of breakthrough CINV. This study investigated the efficacy of "ABH," a topical gel containing lorazepam (Ativan), diphenhydramine (Benadryl), and haloperidol (Haldol), in reducing breakthrough CINV. Adults receiving standard recommended prophylactic antiemetics as outpatients were instructed to use 0.5 mL of the gel topically when they experienced significant CINV. Patients then were contacted retrospectively to respond to a questionnaire rating their nausea and/or vomiting and their response to ABH-gel treatment. The results were collected during two trials: Trial I began in April 2003, and Trial II began in March 2006. During Trial I, 23 patients were evaluated; 17 patients (74%) reported that use of the gel decreased their CINV, with 15 (70%) reporting relief within 30 minutes of its application.Three patients believed that the gel caused sedation; no troubles with skin irritation or muscle spasms were reported. In Trial II, all 10 patients believed that the treatment was effective. When the severity of CINV was quantified on a scale of 0-10, the mean CINV score decreased significantly from a 6.1 before gel application to a 1.7 as evaluated 30 minutes following gel application (P<0.005).Topical use of ABH gel appears to be a promising and safe rescue therapy for breakthrough CINV that occurs despite prophylactic antiemetic therapy. These results warrant further confirmation in a large, randomized, placebo-controlled trial.

AB - Despite their use of prophylactic antiemetic therapies, cancer patients continue to consider chemotherapy-induced nausea and vomiting (CINV) to be a significant problem. Patients frequently use various "breakthrough" medications for these symptoms. Unfortunately, there is a paucity of trials regarding treatment of breakthrough CINV. This study investigated the efficacy of "ABH," a topical gel containing lorazepam (Ativan), diphenhydramine (Benadryl), and haloperidol (Haldol), in reducing breakthrough CINV. Adults receiving standard recommended prophylactic antiemetics as outpatients were instructed to use 0.5 mL of the gel topically when they experienced significant CINV. Patients then were contacted retrospectively to respond to a questionnaire rating their nausea and/or vomiting and their response to ABH-gel treatment. The results were collected during two trials: Trial I began in April 2003, and Trial II began in March 2006. During Trial I, 23 patients were evaluated; 17 patients (74%) reported that use of the gel decreased their CINV, with 15 (70%) reporting relief within 30 minutes of its application.Three patients believed that the gel caused sedation; no troubles with skin irritation or muscle spasms were reported. In Trial II, all 10 patients believed that the treatment was effective. When the severity of CINV was quantified on a scale of 0-10, the mean CINV score decreased significantly from a 6.1 before gel application to a 1.7 as evaluated 30 minutes following gel application (P<0.005).Topical use of ABH gel appears to be a promising and safe rescue therapy for breakthrough CINV that occurs despite prophylactic antiemetic therapy. These results warrant further confirmation in a large, randomized, placebo-controlled trial.

UR - http://www.scopus.com/inward/record.url?scp=38949186751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949186751&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 27

EP - 32

JO - Journal of Supportive Oncology

JF - Journal of Supportive Oncology

SN - 1544-6794

IS - 1

ER -